{ "disease": "small-cell-lung-cancer", "label": "Small cell lung cancer", "url": "https://usebiotransfer.org/disease/small-cell-lung-cancer/", "built": "2026-09-16", "facts_hash": { "answers": "991a274d12b6", "targets": "2299d780ab41" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-16", "trials": "2026-09-16" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "DLL3", "ensembl": "ENSG00000090932", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "ROVALPITUZUMAB TESIRINE": "PHASE_3", "TARLATAMAB": "APPROVAL" }, "approved": [ "TARLATAMAB" ], "n_approved": 1, "approved_for": { "TARLATAMAB": [ "small cell lung carcinoma" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "RB1", "ensembl": "ENSG00000139687", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MYC", "ensembl": "ENSG00000136997", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MYCL", "ensembl": "ENSG00000116990", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "ASCL1", "ensembl": "ENSG00000139352", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "NEUROD1", "ensembl": "ENSG00000162992", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "POU2F3", "ensembl": "ENSG00000137709", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "YAP1", "ensembl": "ENSG00000137693", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SLFN11", "ensembl": "ENSG00000172716", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "BCL2", "ensembl": "ENSG00000171791", "n_drug_entries": 7, "n_distinct_drugs": 5, "drugs": { "APG-2575": "PHASE_3", "NAVITOCLAX": "APPROVAL", "OBATOCLAX": "PHASE_3", "OBLIMERSEN": "APPROVAL", "VENETOCLAX": "APPROVAL" }, "approved": [ "NAVITOCLAX", "OBLIMERSEN", "VENETOCLAX" ], "n_approved": 3, "approved_for": { "NAVITOCLAX": [], "OBLIMERSEN": [], "VENETOCLAX": [ "B-cell chronic lymphocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] } ], "trials": { "by_antigen": { "DLL3": { "n": 75, "n_observational": 3, "n_active": 60, "n_withdrawn": 2, "trials": [ { "nct": "NCT04199741", "title": "PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882058", "title": "DAREON\u2122-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963867", "title": "A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179069", "title": "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348797", "title": "Phase I Clinical Study of \u03b1-PD-L1/DLL3 CAR-T in Patients With R/R SCLC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598306", "title": "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957314", "title": "A Study of Hospital-at-Home for People Receiving Tarlatamab", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07006727", "title": "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016230", "title": "Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037758", "title": "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174583", "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07203053", "title": "A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218146", "title": "A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242547", "title": "Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246304", "title": "TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07249879", "title": "This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07278479", "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07402343", "title": "Tarlatamab for SCLC Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416695", "title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423585", "title": "Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472517", "title": "DAREON \u00ae -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480213", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508852", "title": "68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07564401", "title": "A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07677787", "title": "DLL3-Targeted PET/CT in Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744256", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778316", "title": "Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783477", "title": "A Study of Armored CAR T Cells in People With Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07803848", "title": "Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01901653", "title": "Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674568", "title": "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819999", "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03033511", "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)", "status": "TERMINATED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03061812", "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03086239", "title": "A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03392064", "title": "A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC", "status": "SUSPENDED", "last_update": "2025-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04429087", "title": "A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04885998", "title": "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060016", "title": "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507593", "title": "Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05680922", "title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05740566", "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879978", "title": "A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990738", "title": "DAREON\u2122-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06077500", "title": "DAREON\u1d40\u1d39-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06117774", "title": "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06384482", "title": "SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06736418", "title": "Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745323", "title": "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06816394", "title": "Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328490", "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer", "status": "WITHDRAWN", "last_update": "2026-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699237", "title": "A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07707895", "title": "DAREON\u00ae-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT06348797", "title": "Phase I Clinical Study of \u03b1-PD-L1/DLL3 CAR-T in Patients With R/R SCLC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246304", "title": "TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480213", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07564401", "title": "A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744256", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783477", "title": "A Study of Armored CAR T Cells in People With Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507593", "title": "Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05680922", "title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "DLL3", "tarlatamab", "Imdelltra", "rovalpituzumab", "obrixtamig", "BI 764532", "HPN328", "MK-6070" ] }, "PD-L1": { "n": 570, "n_observational": 67, "n_active": 295, "n_withdrawn": 21, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253964", "title": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467723", "title": "Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499053", "title": "Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550104", "title": "A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585490", "title": "Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04777084", "title": "The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.", "status": "RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04865250", "title": "Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892953", "title": "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951947", "title": "JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992780", "title": "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061550", "title": "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136846", "title": "Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05284539", "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer", "status": "RECRUITING", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317858", "title": "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568212", "title": "Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05623267", "title": "Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT", "status": "RECRUITING", "last_update": "2023-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696782", "title": "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751798", "title": "Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05754203", "title": "Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766800", "title": "Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834413", "title": "Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05837052", "title": "A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC", "status": "RECRUITING", "last_update": "2023-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05903092", "title": "MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05920356", "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110572", "title": "Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation", "status": "RECRUITING", "last_update": "2024-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177925", "title": "A Phase \u2161 Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC", "status": "RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179069", "title": "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188650", "title": "The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study", "status": "RECRUITING", "last_update": "2024-01-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223711", "title": "Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC", "status": "RECRUITING", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06295926", "title": "Serplulimab Combined With CCRT for LS-SCLC.", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371482", "title": "Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)", "status": "RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424899", "title": "A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429696", "title": "PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464068", "title": "AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06467617", "title": "Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475209", "title": "Adebrelimab + Apatinib in SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06480864", "title": "Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-01-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06483282", "title": "A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06484491", "title": "IMPT Dose Escalation for NSCLC (HyDose)", "status": "RECRUITING", "last_update": "2026-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06485544", "title": "Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06497530", "title": "Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498635", "title": "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06512051", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06527898", "title": "Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06529081", "title": "Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545747", "title": "Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562920", "title": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06581419", "title": "A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589778", "title": "A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598527", "title": "Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage \u2161-\u2162 Non-small Cell Lung Cancer: A Phase \u2162, Randomized, Multicenter, Prospective Study", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06610734", "title": "Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616623", "title": "Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623422", "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646276", "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06663098", "title": "Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).", "status": "RECRUITING", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667908", "title": "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680050", "title": "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692738", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712355", "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731270", "title": "Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06739928", "title": "Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC", "status": "RECRUITING", "last_update": "2024-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06758401", "title": "This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06771518", "title": "Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06775275", "title": "A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06848699", "title": "A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06853678", "title": "Second-line Immunotherapy for ES-SCLC", "status": "RECRUITING", "last_update": "2025-03-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908070", "title": "Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908993", "title": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06911606", "title": "Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2025-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06936735", "title": "A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943235", "title": "Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07001618", "title": "Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07055581", "title": "Durvalumab as Consolidation for Patients LS-SCLC", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07096882", "title": "SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection", "status": "RECRUITING", "last_update": "2025-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07111520", "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130032", "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07140315", "title": "DK222 Study at Hopkins", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07141264", "title": "Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07144280", "title": "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07170995", "title": "Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226999", "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07229729", "title": "A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07231445", "title": "Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232849", "title": "A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07250477", "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07253142", "title": "A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07269782", "title": "A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322341", "title": "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361497", "title": "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459751", "title": "A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472517", "title": "DAREON \u00ae -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545954", "title": "DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554339", "title": "A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559786", "title": "A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07583511", "title": "Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07596121", "title": "Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS \u2265 50%", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647094", "title": "A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07654400", "title": "A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739758", "title": "A Study of YL201 in Combination With Serplulimab in Participants With Treatment-na\u00efve Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07754812", "title": "Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846416", "title": "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01903993", "title": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"", "status": "COMPLETED", "last_update": "2019-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905657", "title": "Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)", "status": "COMPLETED", "last_update": "2021-10-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000947", "title": "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007070", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)", "status": "COMPLETED", "last_update": "2020-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02041533", "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)", "status": "COMPLETED", "last_update": "2023-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02087423", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088112", "title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02125461", "title": "A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02142738", "title": "Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)", "status": "COMPLETED", "last_update": "2022-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250326", "title": "Safety and Efficacy Study of Nab\u00ae-Paclitaxel With CC-486 or Nab\u00ae-Paclitaxel With Durvalumab, and Nab\u00ae-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298153", "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352948", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02366143", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367781", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367794", "title": "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]", "status": "COMPLETED", "last_update": "2022-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403271", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404441", "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409342", "title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409355", "title": "A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)", "status": "TERMINATED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02452463", "title": "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy", "status": "TERMINATED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454933", "title": "Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02463994", "title": "A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC", "status": "COMPLETED", "last_update": "2019-02-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492867", "title": "A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02525757", "title": "MPDL3280A With Chemoradiation for Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572843", "title": "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574598", "title": "MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2021-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599454", "title": "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2019-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639026", "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657434", "title": "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02673814", "title": "Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2016-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02710396", "title": "Genetic Predictors of Benefit to Pembrolizumab", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716038", "title": "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC", "status": "COMPLETED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2023-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02748889", "title": "Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02817633", "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02824965", "title": "Pembrolizumab + CVA21 in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848651", "title": "A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "status": "TERMINATED", "last_update": "2023-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927301", "title": "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02994576", "title": "Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003962", "title": "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03004105", "title": "MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2018-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03022500", "title": "Pulmonary sarcomatoid_MEDI4736+Treme", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03041181", "title": "Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor", "status": "TERMINATED", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03048500", "title": "Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery", "status": "UNKNOWN", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050554", "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03059667", "title": "Immunotherapy as Second-line in Patient With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088540", "title": "Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03130764", "title": "Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC", "status": "WITHDRAWN", "last_update": "2017-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03138889", "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03141359", "title": "Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03148327", "title": "Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy", "status": "TERMINATED", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164616", "title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191786", "title": "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Na\u00efve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233724", "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas", "status": "TERMINATED", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262454", "title": "Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03270176", "title": "A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy", "status": "COMPLETED", "last_update": "2022-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "status": "TERMINATED", "last_update": "2023-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03308942", "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319316", "title": "Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)", "status": "WITHDRAWN", "last_update": "2022-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03380871", "title": "A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386929", "title": "Survival Prolongation by Rationale Innovative Genomics", "status": "TERMINATED", "last_update": "2023-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412058", "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03417882", "title": "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC", "status": "TERMINATED", "last_update": "2023-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425006", "title": "Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03438318", "title": "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03446547", "title": "Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447678", "title": "Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.", "status": "UNKNOWN", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455556", "title": "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03456063", "title": "A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498222", "title": "Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin", "status": "WITHDRAWN", "last_update": "2020-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03502330", "title": "APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514719", "title": "PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)", "status": "COMPLETED", "last_update": "2022-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519971", "title": "Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526900", "title": "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na\u00efve Patients With Asymptomatic Brain Metastasis", "status": "COMPLETED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03540420", "title": "Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03563716", "title": "A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Na\u00efve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589547", "title": "Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616691", "title": "Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC", "status": "UNKNOWN", "last_update": "2018-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620669", "title": "1st Line Durvalumab in PS 2 NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "status": "TERMINATED", "last_update": "2026-06-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03644823", "title": "Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03689855", "title": "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "COMPLETED", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03706690", "title": "A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03713944", "title": "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na\u00efve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715205", "title": "Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)", "status": "COMPLETED", "last_update": "2025-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732274", "title": "Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC", "status": "COMPLETED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732664", "title": "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735121", "title": "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03774732", "title": "PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03794544", "title": "Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800134", "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801304", "title": "Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03808480", "title": "Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818776", "title": "Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC", "status": "TERMINATED", "last_update": "2024-02-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03827577", "title": "OMEGA, Local Ablative Therapy in Oligometastatic NSCLC", "status": "UNKNOWN", "last_update": "2020-01-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829319", "title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)", "status": "COMPLETED", "last_update": "2026-02-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03830918", "title": "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833154", "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836066", "title": "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850444", "title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study", "status": "COMPLETED", "last_update": "2023-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03865511", "title": "MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03871153", "title": "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03896074", "title": "Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915951", "title": "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916419", "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922997", "title": "A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03958097", "title": "Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03963414", "title": "A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC", "status": "TERMINATED", "last_update": "2023-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03965468", "title": "Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976518", "title": "Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)", "status": "COMPLETED", "last_update": "2024-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977194", "title": "Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989362", "title": "Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03991403", "title": "Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC", "status": "UNKNOWN", "last_update": "2023-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03994744", "title": "Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC", "status": "UNKNOWN", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03999710", "title": "Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003246", "title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028050", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042558", "title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059887", "title": "Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062708", "title": "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04078152", "title": "Durvalumab Long-Term Safety and Efficacy Study", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082988", "title": "Early Response Evaluation in NSCLC Patients Treated With Immunotherapy", "status": "TERMINATED", "last_update": "2023-10-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099836", "title": "Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib", "status": "TERMINATED", "last_update": "2023-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101357", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411", "status": "TERMINATED", "last_update": "2025-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04108026", "title": "Immunotherapy in Patient With Poor General Condition", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04147351", "title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04153734", "title": "Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) \u226550% Locally Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2019-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04163432", "title": "Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC", "status": "TERMINATED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165096", "title": "KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)", "status": "COMPLETED", "last_update": "2026-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04181788", "title": "Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04194203", "title": "A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Na\u00efve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)", "status": "COMPLETED", "last_update": "2024-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221529", "title": "Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide", "status": "COMPLETED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224337", "title": "Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04239443", "title": "Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer", "status": "UNKNOWN", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245085", "title": "ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245514", "title": "Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249362", "title": "Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy", "status": "COMPLETED", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255836", "title": "Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256421", "title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262388", "title": "A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04267237", "title": "A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287894", "title": "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04294810", "title": "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310020", "title": "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04314297", "title": "Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study", "status": "UNKNOWN", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04325763", "title": "A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)", "status": "UNKNOWN", "last_update": "2022-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334941", "title": "Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351256", "title": "Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356222", "title": "Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04360655", "title": "Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC", "status": "UNKNOWN", "last_update": "2020-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04361825", "title": "Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects", "status": "COMPLETED", "last_update": "2024-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04367311", "title": "Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors \u2265 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372927", "title": "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy", "status": "TERMINATED", "last_update": "2023-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04373369", "title": "Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04381494", "title": "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04392505", "title": "Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04393883", "title": "A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-11-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396457", "title": "Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04402788", "title": "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial", "status": "SUSPENDED", "last_update": "2026-09-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416633", "title": "Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC", "status": "COMPLETED", "last_update": "2024-11-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426825", "title": "A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04440735", "title": "A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04441138", "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449861", "title": "Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04462276", "title": "Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease", "status": "COMPLETED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04470674", "title": "Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (\u2265 50%) NSCLC Patients", "status": "WITHDRAWN", "last_update": "2022-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471415", "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471428", "title": "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472949", "title": "Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04480372", "title": "SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II", "status": "COMPLETED", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487756", "title": "Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512430", "title": "Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524195", "title": "PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04525391", "title": "AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "status": "TERMINATED", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04549428", "title": "Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC", "status": "TERMINATED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560244", "title": "A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment", "status": "UNKNOWN", "last_update": "2020-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560972", "title": "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562337", "title": "SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585477", "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)", "status": "SUSPENDED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602533", "title": "Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04607954", "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04619797", "title": "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622007", "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)", "status": "UNKNOWN", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622228", "title": "Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631029", "title": "Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04636762", "title": "A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655976", "title": "Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660097", "title": "Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665856", "title": "Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04690686", "title": "Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Na\u00efve Patients With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712903", "title": "Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716933", "title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study", "status": "COMPLETED", "last_update": "2025-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716946", "title": "Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04725188", "title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730999", "title": "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745689", "title": "Study of AZD2811 + Durvalumab in ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04748419", "title": "Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762030", "title": "Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04765709", "title": "Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776447", "title": "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04791839", "title": "Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04832854", "title": "A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04841538", "title": "A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors", "status": "WITHDRAWN", "last_update": "2022-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870112", "title": "A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04881045", "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895579", "title": "Lung Cancer With Copanlisib and Durvalumab", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04911166", "title": "Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy", "status": "TERMINATED", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04914897", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)", "status": "TERMINATED", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04919369", "title": "All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921358", "title": "Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923776", "title": "Liver Directed RT + Chemo-immunotherapy for ES-SCLC", "status": "TERMINATED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04924101", "title": "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)", "status": "COMPLETED", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925986", "title": "Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Na\u00efve PD-L1+ Non-Squamous NSCLC", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929041", "title": "Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944173", "title": "SCION: SABR and Checkpoint Inhibition of NSCLC", "status": "WITHDRAWN", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958811", "title": "Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982549", "title": "A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2021-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984811", "title": "NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC", "status": "TERMINATED", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985851", "title": "To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.", "status": "UNKNOWN", "last_update": "2023-12-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989283", "title": "Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992715", "title": "PD-L1 Expression in Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997382", "title": "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007769", "title": "Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008861", "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy", "status": "UNKNOWN", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05089734", "title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092412", "title": "Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111197", "title": "Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128630", "title": "Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.", "status": "UNKNOWN", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161533", "title": "Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial", "status": "WITHDRAWN", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191797", "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198830", "title": "Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05205421", "title": "A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05223647", "title": "Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224141", "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05240131", "title": "A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265650", "title": "Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267392", "title": "Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296603", "title": "Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298423", "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05353257", "title": "A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383001", "title": "Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)", "status": "WITHDRAWN", "last_update": "2022-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403723", "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC", "status": "SUSPENDED", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05416775", "title": "Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443646", "title": "Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients", "status": "UNKNOWN", "last_update": "2024-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443971", "title": "Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen", "status": "TERMINATED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451173", "title": "Combining ICI With SBRT or HypoFrx-RT for ES NSCLC", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468489", "title": "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05479812", "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484583", "title": "Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05496166", "title": "The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-05-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05534113", "title": "Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05565378", "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05595460", "title": "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599789", "title": "Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05609578", "title": "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641493", "title": "A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05675033", "title": "Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05689671", "title": "Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703997", "title": "FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction", "status": "NOT_YET_RECRUITING", "last_update": "2023-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05738317", "title": "Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment", "status": "UNKNOWN", "last_update": "2023-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05746481", "title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05757843", "title": "Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765825", "title": "Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05775796", "title": "Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05781308", "title": "Combination of Paclitaxel-bevacizumab \u00b1 Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787613", "title": "A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796089", "title": "Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807893", "title": "Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases", "status": "COMPLETED", "last_update": "2024-11-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05825625", "title": "NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05844150", "title": "A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05856695", "title": "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882513", "title": "Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882630", "title": "Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911308", "title": "Abequolixron (RGX-104) and Durvalumab in Lung Cancer", "status": "TERMINATED", "last_update": "2025-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932264", "title": "Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05957510", "title": "Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064279", "title": "Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06077500", "title": "DAREON\u1d40\u1d39-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083454", "title": "Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06124118", "title": "Tumor Treating Fields for Locally Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06182800", "title": "Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06195683", "title": "Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS \u2265 50%: a Prospective, Single-center, Single-arm Phase 2 Study.", "status": "UNKNOWN", "last_update": "2024-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06198907", "title": "Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236997", "title": "Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285097", "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299371", "title": "Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06300424", "title": "Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06306560", "title": "A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332950", "title": "Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06334757", "title": "Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06335355", "title": "A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350162", "title": "Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC", "status": "UNKNOWN", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364046", "title": "Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06382129", "title": "A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06405230", "title": "Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419179", "title": "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434103", "title": "Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448312", "title": "A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462105", "title": "Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06478264", "title": "A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06554535", "title": "Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580665", "title": "Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06594874", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597513", "title": "Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06606847", "title": "A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06614621", "title": "A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06672133", "title": "Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06685653", "title": "Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690216", "title": "Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06694454", "title": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "SUSPENDED", "last_update": "2026-09-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06698042", "title": "A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06700421", "title": "Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06719336", "title": "Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06724263", "title": "A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735508", "title": "MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06743555", "title": "Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773156", "title": "Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784206", "title": "Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786312", "title": "A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897579", "title": "Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914050", "title": "Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963502", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982924", "title": "A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998719", "title": "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031154", "title": "A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07035392", "title": "Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063407", "title": "Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07064876", "title": "Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069270", "title": "A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07141771", "title": "An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07146230", "title": "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155122", "title": "Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190027", "title": "Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07200154", "title": "Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07241819", "title": "Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07274384", "title": "Hyperprogression in PD-L1 \u2265 50% NSCLC: a Biomarker Guided Phase 2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281209", "title": "A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283198", "title": "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07318883", "title": "A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357532", "title": "Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07358689", "title": "Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07360743", "title": "Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361484", "title": "Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381543", "title": "Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07398560", "title": "Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416058", "title": "PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 \u226550% Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418866", "title": "FANLUNG-2\uff1aThe Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464327", "title": "A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538271", "title": "A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07560358", "title": "Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07567326", "title": "Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07583550", "title": "Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07672223", "title": "A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07704645", "title": "The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07707895", "title": "DAREON\u00ae-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759492", "title": "Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07798947", "title": "A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07822542", "title": "A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "Tecentriq", "durvalumab", "Imfinzi", "adebrelimab", "serplulimab" ] }, "PD-1": { "n": 682, "n_observational": 62, "n_active": 325, "n_withdrawn": 14, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04144569", "title": "PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253964", "title": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04317534", "title": "Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04613596", "title": "Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04728724", "title": "Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04777084", "title": "The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.", "status": "RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04790682", "title": "LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04966663", "title": "Using ctDNA to Determine Therapies for Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076760", "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05254184", "title": "KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05255302", "title": "De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction", "status": "RECRUITING", "last_update": "2025-04-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05284539", "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer", "status": "RECRUITING", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05286957", "title": "MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC", "status": "RECRUITING", "last_update": "2023-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317858", "title": "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431270", "title": "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468242", "title": "Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab \u00b1 Bevacizumab and Definitive Concurrent Chemoradiation Therapy", "status": "RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05681780", "title": "Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05701176", "title": "A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05715229", "title": "Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05745350", "title": "First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC", "status": "RECRUITING", "last_update": "2025-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751798", "title": "Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05754203", "title": "Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766800", "title": "Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05798845", "title": "The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800340", "title": "Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC", "status": "RECRUITING", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834413", "title": "Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05837052", "title": "A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC", "status": "RECRUITING", "last_update": "2023-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05899608", "title": "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05920356", "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06030258", "title": "IN10018 Combination Therapy in Treatment-na\u00efve ES-SCLC", "status": "RECRUITING", "last_update": "2025-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06032052", "title": "Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients", "status": "RECRUITING", "last_update": "2024-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095583", "title": "Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06096844", "title": "Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06127303", "title": "Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06216301", "title": "LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236438", "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256237", "title": "Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial", "status": "RECRUITING", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06269211", "title": "Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression", "status": "RECRUITING", "last_update": "2024-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06275360", "title": "Repositioning Immunotherapy in VetArans With Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06295926", "title": "Serplulimab Combined With CCRT for LS-SCLC.", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362369", "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06379087", "title": "Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC", "status": "RECRUITING", "last_update": "2025-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06388031", "title": "ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI", "status": "RECRUITING", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06416410", "title": "JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06426511", "title": "ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06427941", "title": "A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06437977", "title": "Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06451497", "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06473961", "title": "A Phase Ib Study of GC101 in NSCLC", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475300", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06497530", "title": "Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536868", "title": "Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545747", "title": "Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561685", "title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598527", "title": "Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage \u2161-\u2162 Non-small Cell Lung Cancer: A Phase \u2162, Randomized, Multicenter, Prospective Study", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06617936", "title": "Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623136", "title": "A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623422", "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646276", "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06659042", "title": "Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667154", "title": "Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy", "status": "RECRUITING", "last_update": "2024-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692738", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06719700", "title": "Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731270", "title": "Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06734702", "title": "Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745908", "title": "Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06749860", "title": "Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06754644", "title": "A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06758401", "title": "This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764771", "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06800339", "title": "A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06838208", "title": "Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06848699", "title": "A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868732", "title": "Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06877299", "title": "Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage \u2161A-\u2162B Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06896422", "title": "Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06902272", "title": "ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908304", "title": "A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908993", "title": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06911606", "title": "Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2025-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06924606", "title": "Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926790", "title": "Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939127", "title": "Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06947694", "title": "A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases", "status": "RECRUITING", "last_update": "2025-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06969612", "title": "A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06977074", "title": "PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC", "status": "RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07001618", "title": "Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010263", "title": "A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014202", "title": "Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy", "status": "RECRUITING", "last_update": "2025-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07039656", "title": "Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07085182", "title": "Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer\uff1aA Prospective, Single-Arm, Phase II Study", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07086300", "title": "Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07086456", "title": "Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07089199", "title": "Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07094113", "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07098988", "title": "Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07109401", "title": "Perioperative Immunotherapy for Resectable Limited-Stage SCLC", "status": "RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07111520", "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07120282", "title": "Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130032", "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07131319", "title": "SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07140315", "title": "DK222 Study at Hopkins", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07158489", "title": "Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07169994", "title": "A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07170995", "title": "Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174908", "title": "A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198217", "title": "Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07208773", "title": "A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07231445", "title": "Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251582", "title": "Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07253142", "title": "A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07264647", "title": "Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07269782", "title": "A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320105", "title": "Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07330037", "title": "TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07330596", "title": "QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07355205", "title": "First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07362459", "title": "A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07376707", "title": "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408635", "title": "IBI363 (PD-1/IL-2\u03b1-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07413042", "title": "A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416474", "title": "RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425795", "title": "Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07468071", "title": "Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments", "status": "RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486817", "title": "Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502300", "title": "A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528274", "title": "Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07541170", "title": "A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554846", "title": "Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07560111", "title": "A Phase II Study of GC101 in NSCLC", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07583511", "title": "Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07596121", "title": "Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS \u2265 50%", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07609121", "title": "Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637448", "title": "EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647094", "title": "A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662395", "title": "SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739758", "title": "A Study of YL201 in Combination With Serplulimab in Participants With Treatment-na\u00efve Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744698", "title": "Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07754812", "title": "Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07815223", "title": "A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295827", "title": "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)", "status": "COMPLETED", "last_update": "2019-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01642004", "title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)", "status": "COMPLETED", "last_update": "2022-12-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01721759", "title": "Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens", "status": "COMPLETED", "last_update": "2022-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01840579", "title": "Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)", "status": "COMPLETED", "last_update": "2021-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905657", "title": "Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)", "status": "COMPLETED", "last_update": "2021-10-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928576", "title": "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.", "status": "COMPLETED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007070", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)", "status": "COMPLETED", "last_update": "2020-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02041533", "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)", "status": "COMPLETED", "last_update": "2023-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02046733", "title": "Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease", "status": "COMPLETED", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02066636", "title": "A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen", "status": "COMPLETED", "last_update": "2022-10-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02142738", "title": "Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)", "status": "COMPLETED", "last_update": "2022-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02175017", "title": "ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02247349", "title": "BMS-986012 in Relapsed/Refractory SCLC", "status": "COMPLETED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343952", "title": "Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "status": "TERMINATED", "last_update": "2020-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02350764", "title": "Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02364609", "title": "Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib", "status": "COMPLETED", "last_update": "2024-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02382406", "title": "Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC", "status": "TERMINATED", "last_update": "2023-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393625", "title": "Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02402920", "title": "Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404441", "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423954", "title": "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02434081", "title": "NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02439450", "title": "A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02444741", "title": "Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02466568", "title": "Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung", "status": "WITHDRAWN", "last_update": "2019-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02469701", "title": "Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease", "status": "TERMINATED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475213", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02477826", "title": "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492568", "title": "Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC", "status": "COMPLETED", "last_update": "2020-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02526017", "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538666", "title": "An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy", "status": "COMPLETED", "last_update": "2023-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564380", "title": "Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)", "status": "TERMINATED", "last_update": "2022-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574598", "title": "MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2021-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575404", "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients", "status": "COMPLETED", "last_update": "2023-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02578680", "title": "Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)", "status": "COMPLETED", "last_update": "2024-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02582125", "title": "ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02591615", "title": "Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC", "status": "COMPLETED", "last_update": "2022-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "status": "COMPLETED", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02613507", "title": "Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02621398", "title": "Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02637531", "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659059", "title": "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02661100", "title": "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients", "status": "WITHDRAWN", "last_update": "2016-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "status": "TERMINATED", "last_update": "2024-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664181", "title": "Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02684461", "title": "Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel", "status": "COMPLETED", "last_update": "2022-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02696993", "title": "Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02710396", "title": "Genetic Predictors of Benefit to Pembrolizumab", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713867", "title": "A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks", "status": "COMPLETED", "last_update": "2023-02-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02718066", "title": "Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02733159", "title": "Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2", "status": "COMPLETED", "last_update": "2025-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02733250", "title": "Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02817633", "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02824965", "title": "Pembrolizumab + CVA21 in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02831933", "title": "Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02840994", "title": "A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02846792", "title": "Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869789", "title": "An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02897765", "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer", "status": "COMPLETED", "last_update": "2021-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02909452", "title": "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924233", "title": "Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954991", "title": "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02967133", "title": "A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02978404", "title": "Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases", "status": "COMPLETED", "last_update": "2024-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03001882", "title": "An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2024-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025256", "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03041181", "title": "Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor", "status": "TERMINATED", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043599", "title": "Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03048500", "title": "Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery", "status": "UNKNOWN", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03049618", "title": "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475", "status": "COMPLETED", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050554", "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081689", "title": "Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087760", "title": "Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088540", "title": "Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03090737", "title": "Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03138889", "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03150875", "title": "A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158129", "title": "Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184571", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190174", "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "status": "COMPLETED", "last_update": "2025-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03195491", "title": "A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia", "status": "COMPLETED", "last_update": "2024-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217071", "title": "Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233724", "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas", "status": "TERMINATED", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03253068", "title": "Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03265080", "title": "A Study of ADXS-NEO Expressing Personalized Tumor Antigens", "status": "TERMINATED", "last_update": "2023-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03282435", "title": "Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody", "status": "UNKNOWN", "last_update": "2017-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03285321", "title": "Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03293680", "title": "Pembrolizumab in Elderly Patients With Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03299088", "title": "Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03307759", "title": "Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03308942", "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03311672", "title": "T-Cell PET Imaging With [18F]F-AraG in Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313544", "title": "Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03322566", "title": "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03325166", "title": "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases", "status": "TERMINATED", "last_update": "2022-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03325816", "title": "Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347123", "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03351361", "title": "Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients", "status": "COMPLETED", "last_update": "2023-03-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03353675", "title": "A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358875", "title": "Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03361228", "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2020-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03366766", "title": "Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377023", "title": "Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03380871", "title": "A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03383302", "title": "SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects", "status": "COMPLETED", "last_update": "2026-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386929", "title": "Survival Prolongation by Rationale Innovative Genomics", "status": "TERMINATED", "last_update": "2023-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03396497", "title": "Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2019-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03402880", "title": "ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406715", "title": "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)", "status": "TERMINATED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412058", "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03417882", "title": "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC", "status": "TERMINATED", "last_update": "2023-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425006", "title": "Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425331", "title": "Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC", "status": "TERMINATED", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03444766", "title": "Study of Nivolumab for Advanced Cancers in India", "status": "COMPLETED", "last_update": "2020-12-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447678", "title": "Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.", "status": "UNKNOWN", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469960", "title": "Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473925", "title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)", "status": "COMPLETED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03502330", "title": "APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509584", "title": "Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03513666", "title": "A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment", "status": "COMPLETED", "last_update": "2023-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03525782", "title": "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC", "status": "UNKNOWN", "last_update": "2018-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03542461", "title": "Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)", "status": "UNKNOWN", "last_update": "2022-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03546361", "title": "CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03582475", "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03594747", "title": "A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623776", "title": "Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.", "status": "WITHDRAWN", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "status": "TERMINATED", "last_update": "2026-06-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "status": "COMPLETED", "last_update": "2022-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03637803", "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03662074", "title": "Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03663166", "title": "Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03663205", "title": "A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03669523", "title": "Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03679767", "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)", "status": "COMPLETED", "last_update": "2023-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715205", "title": "Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)", "status": "COMPLETED", "last_update": "2025-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03728361", "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732664", "title": "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735290", "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer", "status": "TERMINATED", "last_update": "2022-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735628", "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03745222", "title": "A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755115", "title": "SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2019-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758781", "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03774732", "title": "PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775850", "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03777124", "title": "Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03808480", "title": "Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811379", "title": "Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy", "status": "UNKNOWN", "last_update": "2019-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03825510", "title": "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect", "status": "COMPLETED", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829319", "title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)", "status": "COMPLETED", "last_update": "2026-02-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03846310", "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03847519", "title": "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03848611", "title": "CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2020-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850067", "title": "A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850444", "title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study", "status": "COMPLETED", "last_update": "2023-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03856411", "title": "A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-02-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884192", "title": "Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2019-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894618", "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas", "status": "COMPLETED", "last_update": "2025-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03904108", "title": "Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy", "status": "TERMINATED", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03904719", "title": "CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)", "status": "UNKNOWN", "last_update": "2020-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924050", "title": "Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI", "status": "COMPLETED", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03952403", "title": "A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2023-08-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03958045", "title": "Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03958097", "title": "Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970746", "title": "Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03987867", "title": "Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989362", "title": "Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03994744", "title": "Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC", "status": "UNKNOWN", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03996473", "title": "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases", "status": "TERMINATED", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005716", "title": "Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04012606", "title": "Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013542", "title": "Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04025879", "title": "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027946", "title": "LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032418", "title": "Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032847", "title": "ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04047186", "title": "Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04079712", "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082988", "title": "Early Response Evaluation in NSCLC Patients Treated With Immunotherapy", "status": "TERMINATED", "last_update": "2023-10-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04083599", "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04085250", "title": "Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy", "status": "UNKNOWN", "last_update": "2024-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04130516", "title": "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04137900", "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies", "status": "UNKNOWN", "last_update": "2024-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04142931", "title": "Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2021-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04144608", "title": "Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC", "status": "COMPLETED", "last_update": "2024-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04153734", "title": "Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) \u226550% Locally Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2019-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158440", "title": "Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165096", "title": "KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)", "status": "COMPLETED", "last_update": "2026-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04181788", "title": "Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193098", "title": "Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04194944", "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04205552", "title": "Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04211896", "title": "Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2019-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238169", "title": "Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04239443", "title": "Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer", "status": "UNKNOWN", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04261439", "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "status": "TERMINATED", "last_update": "2025-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263051", "title": "Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263090", "title": "Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266730", "title": "Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04304248", "title": "Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04314297", "title": "Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study", "status": "UNKNOWN", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04316351", "title": "Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance", "status": "UNKNOWN", "last_update": "2020-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04325763", "title": "A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)", "status": "UNKNOWN", "last_update": "2022-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04331626", "title": "Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC", "status": "UNKNOWN", "last_update": "2020-04-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358237", "title": "Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04360655", "title": "Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC", "status": "UNKNOWN", "last_update": "2020-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04363255", "title": "First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC", "status": "UNKNOWN", "last_update": "2020-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04374877", "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379635", "title": "Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379739", "title": "Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04393883", "title": "A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-11-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396457", "title": "Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405674", "title": "Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC", "status": "UNKNOWN", "last_update": "2021-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04418648", "title": "Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy", "status": "TERMINATED", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434560", "title": "Neoadjuvant Immunotherapy in Brain Metastases", "status": "TERMINATED", "last_update": "2022-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04459663", "title": "JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04475939", "title": "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489862", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-07-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04507217", "title": "Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04507906", "title": "Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC", "status": "COMPLETED", "last_update": "2022-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524195", "title": "PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04533451", "title": "Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542369", "title": "Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544644", "title": "A Study of Combination Therapy in NSCLC", "status": "UNKNOWN", "last_update": "2020-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547504", "title": "PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 \u2265 50 %", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04549428", "title": "Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC", "status": "TERMINATED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04564157", "title": "New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579757", "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606472", "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610658", "title": "Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC", "status": "TERMINATED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04612673", "title": "A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2020-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04613804", "title": "Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy", "status": "UNKNOWN", "last_update": "2020-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04620837", "title": "Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy", "status": "UNKNOWN", "last_update": "2020-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622007", "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)", "status": "UNKNOWN", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623775", "title": "A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04638582", "title": "Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04691388", "title": "A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699188", "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699721", "title": "Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716933", "title": "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study", "status": "COMPLETED", "last_update": "2025-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04721223", "title": "JAB-3068 Activity in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04725188", "title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04725448", "title": "Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma", "status": "UNKNOWN", "last_update": "2021-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04731909", "title": "Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-02-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04746924", "title": "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer", "status": "TERMINATED", "last_update": "2026-05-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04749602", "title": "Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.", "status": "COMPLETED", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04758949", "title": "FL-101 in Surgically Resectable Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04772287", "title": "Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)", "status": "NOT_YET_RECRUITING", "last_update": "2021-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776447", "title": "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04782089", "title": "Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04790539", "title": "a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797702", "title": "Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.", "status": "TERMINATED", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04865705", "title": "Neoadjuvant Chemotherapy and Tilelizumab in Stage III\uff08cTNM-IIIA.IIIB\uff09Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879849", "title": "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers", "status": "COMPLETED", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884282", "title": "Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900363", "title": "A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04909034", "title": "A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04914897", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)", "status": "TERMINATED", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921358", "title": "Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04924101", "title": "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)", "status": "COMPLETED", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925986", "title": "Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Na\u00efve PD-L1+ Non-Squamous NSCLC", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929041", "title": "Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943900", "title": "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951583", "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma", "status": "UNKNOWN", "last_update": "2024-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04952597", "title": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04956640", "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964479", "title": "A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04966676", "title": "Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer", "status": "TERMINATED", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04967625", "title": "A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC", "status": "UNKNOWN", "last_update": "2021-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04970043", "title": "Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment", "status": "UNKNOWN", "last_update": "2021-07-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996771", "title": "Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04998474", "title": "FRAME-001 Personalized Vaccine in NSCLC", "status": "UNKNOWN", "last_update": "2021-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05003037", "title": "Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008861", "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy", "status": "UNKNOWN", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05021328", "title": "Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC", "status": "COMPLETED", "last_update": "2025-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05022394", "title": "Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study", "status": "WITHDRAWN", "last_update": "2022-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05027100", "title": "Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05055583", "title": "Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC", "status": "UNKNOWN", "last_update": "2021-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05058560", "title": "Tislelizumab in Addition to BACE in Patients with NSCLC", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068427", "title": "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05089734", "title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05111197", "title": "Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05127590", "title": "RBN-2397 in Combination With Pembrolizumab in Patients With SCCL", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162196", "title": "The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170581", "title": "Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176925", "title": "Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC", "status": "TERMINATED", "last_update": "2024-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05192681", "title": "Tislelizumab as Cross-line Treatment for Advanced NSCLC", "status": "UNKNOWN", "last_update": "2022-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207904", "title": "Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases", "status": "UNKNOWN", "last_update": "2022-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05212922", "title": "A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC", "status": "WITHDRAWN", "last_update": "2023-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224141", "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05226728", "title": "Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228496", "title": "A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC", "status": "UNKNOWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229614", "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease", "status": "UNKNOWN", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05248022", "title": "Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure", "status": "UNKNOWN", "last_update": "2024-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265650", "title": "Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267392", "title": "Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05273814", "title": "Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer", "status": "UNKNOWN", "last_update": "2022-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298423", "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319574", "title": "SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05346952", "title": "A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05353257", "title": "A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05354700", "title": "A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05375084", "title": "SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation", "status": "TERMINATED", "last_update": "2024-12-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386888", "title": "A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC", "status": "COMPLETED", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05394233", "title": "Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC", "status": "UNKNOWN", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05397093", "title": "ITIL-306 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401786", "title": "Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443646", "title": "Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients", "status": "UNKNOWN", "last_update": "2024-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468489", "title": "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05479812", "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05500092", "title": "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05505877", "title": "Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05519865", "title": "A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC", "status": "COMPLETED", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05565378", "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577702", "title": "Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599789", "title": "Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05609578", "title": "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05611879", "title": "Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage \u2162 NSCLC", "status": "UNKNOWN", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633667", "title": "Study of Novel Treatment Combinations in Patients With Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05635708", "title": "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641493", "title": "A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05651022", "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05653882", "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05675033", "title": "Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05676931", "title": "Study With Various Immunotherapy Treatments in Participants With Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05689671", "title": "Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718167", "title": "TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2023-02-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05757492", "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05758116", "title": "Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients", "status": "COMPLETED", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760053", "title": "Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765825", "title": "Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05775796", "title": "Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787613", "title": "A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05789069", "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791097", "title": "Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.", "status": "WITHDRAWN", "last_update": "2023-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05798533", "title": "Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)", "status": "UNKNOWN", "last_update": "2023-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807893", "title": "Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases", "status": "COMPLETED", "last_update": "2024-11-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829057", "title": "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840016", "title": "AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05842018", "title": "Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)", "status": "UNKNOWN", "last_update": "2023-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05846646", "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC", "status": "TERMINATED", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05847764", "title": "Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "UNKNOWN", "last_update": "2023-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05878028", "title": "L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC", "status": "UNKNOWN", "last_update": "2024-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882513", "title": "Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882630", "title": "Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05887492", "title": "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888402", "title": "Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888831", "title": "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891080", "title": "Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05892237", "title": "CIETAI and Sequential Radiotherapy in Squamous Lung Cancer", "status": "UNKNOWN", "last_update": "2023-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05896059", "title": "A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC", "status": "UNKNOWN", "last_update": "2023-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900921", "title": "Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05901584", "title": "Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05902260", "title": "The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955105", "title": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05957510", "title": "Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05962021", "title": "Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990127", "title": "A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055465", "title": "Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065813", "title": "Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091943", "title": "Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06094296", "title": "A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2025-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06099782", "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136910", "title": "Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06139419", "title": "The Impact of Thymosin \u03b1-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC", "status": "COMPLETED", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06140407", "title": "Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06142617", "title": "A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06151574", "title": "Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06154967", "title": "To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2023-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06195683", "title": "Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS \u2265 50%: a Prospective, Single-center, Single-arm Phase 2 Study.", "status": "UNKNOWN", "last_update": "2024-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06208033", "title": "SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2024-01-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06212752", "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06219174", "title": "Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)", "status": "SUSPENDED", "last_update": "2026-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06246110", "title": "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285097", "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287593", "title": "The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06293690", "title": "Toripalimab Combined With SBRT for NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06334757", "title": "Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348199", "title": "A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350162", "title": "Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC", "status": "UNKNOWN", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357598", "title": "Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage \u2162 Unresectable Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-04-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364046", "title": "Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375109", "title": "PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06382129", "title": "A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06403111", "title": "FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC", "status": "UNKNOWN", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06405230", "title": "Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06406673", "title": "A Phase II Clinical Study of Cadonilimab in Treatment-na\u00efve or Relapsed Extensive Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06430866", "title": "Pharmacokinetic Similarity Between ABP 234 and Keytruda\u00ae (Pembrolizumab)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06441344", "title": "Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06447662", "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448312", "title": "A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06456138", "title": "Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462105", "title": "Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475755", "title": "Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06542731", "title": "An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544655", "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06554535", "title": "Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580665", "title": "Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607926", "title": "Neoadjuvant With T\u03b11 Plus Immuno-chemotherapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06614231", "title": "Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06648200", "title": "Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06698042", "title": "A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06704620", "title": "Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist\uff08Diphenhydramine\uff09in Advanced and Metastatic Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06704724", "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06706219", "title": "Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709274", "title": "Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732258", "title": "Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC", "status": "WITHDRAWN", "last_update": "2026-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793228", "title": "Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06799286", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851819", "title": "Tislelizumab in Combination with Chemotherapy \u00b1 Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06883552", "title": "An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06883630", "title": "A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897579", "title": "Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908733", "title": "Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06946797", "title": "A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06951841", "title": "Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06966583", "title": "NAD+ Supplement\uff08NMN\uff09With Radioimmunotherapy in Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06977828", "title": "A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06984588", "title": "A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07053215", "title": "Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07064876", "title": "Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07073183", "title": "Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)", "status": "WITHDRAWN", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07097948", "title": "Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07103408", "title": "A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134413", "title": "QL1706/Bevacizumab \u00b1 Chemotherapy in Post-ICI Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07141771", "title": "An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07146230", "title": "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155122", "title": "Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07160335", "title": "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda\u00ae in Multiple Resected Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190027", "title": "Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07231575", "title": "Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07286942", "title": "Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07318636", "title": "NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07318883", "title": "A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07358689", "title": "Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07360132", "title": "Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07360743", "title": "Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361484", "title": "Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07376499", "title": "Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07383116", "title": "Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416058", "title": "PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 \u226550% Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418866", "title": "FANLUNG-2\uff1aThe Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07420439", "title": "Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432984", "title": "Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07438600", "title": "Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07477808", "title": "Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07485920", "title": "A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07493980", "title": "Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07550842", "title": "A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559929", "title": "A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07561983", "title": "Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07576725", "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07608159", "title": "Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617389", "title": "Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618793", "title": "Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07623642", "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07633873", "title": "SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC\uff08SYNSTAR 04\uff09", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662811", "title": "SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07672223", "title": "A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683832", "title": "Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07698054", "title": "Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07715396", "title": "Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739186", "title": "A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739199", "title": "A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756645", "title": "A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07775040", "title": "Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802821", "title": "A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-na\u00efve Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07819578", "title": "Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07822542", "title": "A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 2, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03525782", "title": "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC", "status": "UNKNOWN", "last_update": "2018-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04137900", "title": "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies", "status": "UNKNOWN", "last_update": "2024-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193098", "title": "Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489862", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-07-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07318636", "title": "NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "nivolumab", "pembrolizumab", "toripalimab", "tislelizumab", "serplulimab" ] }, "CTLA-4": { "n": 203, "n_observational": 23, "n_active": 77, "n_withdrawn": 7, "trials": [ { "nct": "NCT04499053", "title": "Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585490", "title": "Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04933903", "title": "BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05254184", "title": "KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05715229", "title": "Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362369", "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364917", "title": "DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492421", "title": "Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.", "status": "RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532591", "title": "Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC", "status": "RECRUITING", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769971", "title": "Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793813", "title": "Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06840782", "title": "First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897046", "title": "Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC", "status": "RECRUITING", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926790", "title": "Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07103395", "title": "A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07330596", "title": "QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07355205", "title": "First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07391670", "title": "A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410975", "title": "Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07452003", "title": "An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07563738", "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07623369", "title": "A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039091", "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00312975", "title": "Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2012-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00527735", "title": "Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2018-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00685750", "title": "Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma", "status": "TERMINATED", "last_update": "2019-06-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01165216", "title": "Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01285609", "title": "Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin", "status": "COMPLETED", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01331525", "title": "The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450761", "title": "Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone", "status": "COMPLETED", "last_update": "2020-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01454102", "title": "Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)", "status": "COMPLETED", "last_update": "2021-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471197", "title": "Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01820754", "title": "Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01840579", "title": "Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)", "status": "COMPLETED", "last_update": "2021-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01936961", "title": "Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01998126", "title": "Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000947", "title": "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039674", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040064", "title": "Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients", "status": "COMPLETED", "last_update": "2016-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02046733", "title": "Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease", "status": "COMPLETED", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02179671", "title": "Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02221739", "title": "Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02259621", "title": "Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02279732", "title": "Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02350764", "title": "Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352948", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381314", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403193", "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02477826", "title": "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538666", "title": "An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy", "status": "COMPLETED", "last_update": "2023-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639026", "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658890", "title": "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread", "status": "COMPLETED", "last_update": "2023-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659059", "title": "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02696993", "title": "Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701400", "title": "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02750514", "title": "An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2021-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02771626", "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2023-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02864251", "title": "A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy", "status": "COMPLETED", "last_update": "2023-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869789", "title": "An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922764", "title": "A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer", "status": "COMPLETED", "last_update": "2025-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02998528", "title": "A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03001882", "title": "An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2024-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03022500", "title": "Pulmonary sarcomatoid_MEDI4736+Treme", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043599", "title": "Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043872", "title": "Durvalumab \u00b1 Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03048136", "title": "A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03057106", "title": "Durvalumab and Tremelimumab \u00b1 Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03083691", "title": "BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer", "status": "COMPLETED", "last_update": "2024-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03085849", "title": "SGI-110 Plus Durvalumab/Tremelimumab in SCLC", "status": "COMPLETED", "last_update": "2018-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03091491", "title": "Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03130764", "title": "Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC", "status": "WITHDRAWN", "last_update": "2017-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158129", "title": "Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164616", "title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03168464", "title": "Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)", "status": "TERMINATED", "last_update": "2023-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03215706", "title": "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03223155", "title": "Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03237377", "title": "Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03256136", "title": "Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC", "status": "COMPLETED", "last_update": "2020-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262779", "title": "Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2025-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "status": "TERMINATED", "last_update": "2023-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03285321", "title": "Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03302234", "title": "Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)", "status": "COMPLETED", "last_update": "2023-09-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319316", "title": "Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)", "status": "WITHDRAWN", "last_update": "2022-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333616", "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347123", "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03351361", "title": "Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients", "status": "COMPLETED", "last_update": "2023-03-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377023", "title": "Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03391869", "title": "Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03406715", "title": "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)", "status": "TERMINATED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409614", "title": "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425331", "title": "Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC", "status": "TERMINATED", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430063", "title": "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer", "status": "TERMINATED", "last_update": "2022-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468985", "title": "Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469960", "title": "Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509584", "title": "Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03515629", "title": "REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer", "status": "TERMINATED", "last_update": "2022-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03527251", "title": "Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2018-05-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564197", "title": "18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03573947", "title": "Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC", "status": "COMPLETED", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575793", "title": "A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580694", "title": "Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2020-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03581487", "title": "Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03639714", "title": "A Study of a Personalized Neoantigen Cancer Vaccine", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647163", "title": "Ph I/II Trial of Systemic VSV-IFN\u03b2-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03663166", "title": "Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03670056", "title": "Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03673332", "title": "Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693612", "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739710", "title": "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03752398", "title": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03761017", "title": "MGD019 DART\u00ae Protein in Unresectable/Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03838848", "title": "KN046 in Patients With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03860272", "title": "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03953235", "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03963414", "title": "A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC", "status": "TERMINATED", "last_update": "2023-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03965468", "title": "Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975114", "title": "A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989362", "title": "Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03994393", "title": "Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013542", "title": "Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04026412", "title": "A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery", "status": "COMPLETED", "last_update": "2025-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04043195", "title": "Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074967", "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04079712", "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04141644", "title": "Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04151563", "title": "A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy", "status": "WITHDRAWN", "last_update": "2023-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04250246", "title": "A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1", "status": "UNKNOWN", "last_update": "2020-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287894", "title": "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04418167", "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations", "status": "SUSPENDED", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434560", "title": "Neoadjuvant Immunotherapy in Brain Metastases", "status": "TERMINATED", "last_update": "2022-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471415", "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544644", "title": "A Study of Combination Therapy in NSCLC", "status": "UNKNOWN", "last_update": "2020-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04571632", "title": "Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606472", "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610658", "title": "Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC", "status": "TERMINATED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625699", "title": "Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment", "status": "WITHDRAWN", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929041", "title": "Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951583", "title": "Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma", "status": "UNKNOWN", "last_update": "2024-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04966676", "title": "Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer", "status": "TERMINATED", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005273", "title": "A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05012254", "title": "Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05118334", "title": "IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2023-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144529", "title": "A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Na\u00efve Patients With Metastatic NSCLC", "status": "TERMINATED", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05303493", "title": "Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383001", "title": "Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)", "status": "WITHDRAWN", "last_update": "2022-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401786", "title": "Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420220", "title": "Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05505825", "title": "A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05597800", "title": "Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome", "status": "NOT_YET_RECRUITING", "last_update": "2022-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05598853", "title": "Intrathecal Double Checkpoint Inhibition", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620134", "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05671510", "title": "ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788926", "title": "A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)", "status": "TERMINATED", "last_update": "2025-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816499", "title": "Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2024-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05901584", "title": "Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06173505", "title": "Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06322108", "title": "Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06406673", "title": "A Phase II Clinical Study of Cadonilimab in Treatment-na\u00efve or Relapsed Extensive Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424821", "title": "Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC", "status": "UNKNOWN", "last_update": "2024-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06477523", "title": "Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06620822", "title": "Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06790303", "title": "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2", "status": "TERMINATED", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06946797", "title": "A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07083375", "title": "A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07103408", "title": "A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134413", "title": "QL1706/Bevacizumab \u00b1 Chemotherapy in Post-ICI Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07200947", "title": "A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07286942", "title": "Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07349225", "title": "Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416058", "title": "PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 \u226550% Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07661966", "title": "Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01820754", "title": "Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CTLA-4", "ipilimumab", "tremelimumab" ] }, "PARP": { "n": 84, "n_observational": 2, "n_active": 29, "n_withdrawn": 3, "trials": [ { "nct": "NCT04170946", "title": "Talazoparib and Thoracic RT for ES-SCLC", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550104", "title": "A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05123482", "title": "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568212", "title": "Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05623319", "title": "Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)", "status": "RECRUITING", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718323", "title": "Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217757", "title": "Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06931626", "title": "Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371663", "title": "An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01266447", "title": "Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer", "status": "COMPLETED", "last_update": "2019-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01282333", "title": "Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2013-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01286987", "title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors", "status": "COMPLETED", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01386385", "title": "Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513174", "title": "Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone", "status": "COMPLETED", "last_update": "2024-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560104", "title": "A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01562210", "title": "Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01638546", "title": "Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01642251", "title": "Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01657799", "title": "Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01788332", "title": "Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)", "status": "UNKNOWN", "last_update": "2018-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02106546", "title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117167", "title": "SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients", "status": "COMPLETED", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264990", "title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289690", "title": "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02412371", "title": "A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2020-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02446704", "title": "Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy", "status": "UNKNOWN", "last_update": "2022-02-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02482311", "title": "Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02498613", "title": "A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02511795", "title": "AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-11-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537561", "title": "Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2016-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02567396", "title": "Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction", "status": "WITHDRAWN", "last_update": "2017-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02679963", "title": "Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02769962", "title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02899728", "title": "Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02944396", "title": "Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03009682", "title": "Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations", "status": "COMPLETED", "last_update": "2021-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03221400", "title": "PEN-866 in Patients With Advanced Solid Malignancies", "status": "UNKNOWN", "last_update": "2022-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03227016", "title": "Study in Patients With SCLC of Veliparib in Combination With Topotecan", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03307785", "title": "Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03308942", "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03428607", "title": "Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]", "status": "COMPLETED", "last_update": "2021-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516084", "title": "A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-12-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03532880", "title": "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672773", "title": "Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03830918", "title": "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03958045", "title": "Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976323", "title": "Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976362", "title": "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)", "status": "COMPLETED", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173507", "title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209595", "title": "PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334941", "title": "Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04380636", "title": "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04475939", "title": "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "status": "TERMINATED", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592237", "title": "Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Na\u00efve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04701307", "title": "Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04728230", "title": "Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04782089", "title": "Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04826341", "title": "A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors", "status": "COMPLETED", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04939662", "title": "Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects", "status": "COMPLETED", "last_update": "2024-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002868", "title": "Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162196", "title": "The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245994", "title": "An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese", "status": "UNKNOWN", "last_update": "2022-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392686", "title": "PD1 and PARP for Maintenance Therapy in NSLLC", "status": "UNKNOWN", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411679", "title": "EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573373", "title": "Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05975944", "title": "Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06130254", "title": "Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers", "status": "TERMINATED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419179", "title": "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07453394", "title": "QLS5132 Combination Therapy in Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PARP", "olaparib", "talazoparib", "niraparib", "veliparib" ] }, "B7-H3": { "n": 35, "n_observational": 1, "n_active": 29, "n_withdrawn": 2, "trials": [ { "nct": "NCT04165070", "title": "KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na\u00efve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05914116", "title": "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203210", "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498479", "title": "ARTEMIS-008\uff1aHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-10-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06621563", "title": "Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780085", "title": "A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780098", "title": "Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06822543", "title": "A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07099898", "title": "A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07181473", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07189871", "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07503808", "title": "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381314", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628535", "title": "Safety Study of MGD009 in B7-H3-expressing Tumors", "status": "TERMINATED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05280470", "title": "Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865990", "title": "HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06052423", "title": "ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06526624", "title": "A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564844", "title": "A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676917", "title": "Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases", "status": "WITHDRAWN", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963502", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063407", "title": "Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07076095", "title": "A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464327", "title": "A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509034", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07509034", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "B7-H3", "CD276", "ifinatamab", "I-DXd", "HS-20093" ] }, "SEZ6": { "n": 3, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT07155174", "title": "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07365241", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599984", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "SEZ6", "ABBV-706" ] }, "LSD1": { "n": 10, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06287775", "title": "Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207395", "title": "A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.", "status": "RECRUITING", "last_update": "2025-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07517198", "title": "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034123", "title": "Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma", "status": "TERMINATED", "last_update": "2019-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02712905", "title": "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03600649", "title": "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas", "status": "UNKNOWN", "last_update": "2023-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04350463", "title": "A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191797", "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420636", "title": "Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET", "status": "TERMINATED", "last_update": "2025-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "LSD1", "iadademstat", "bomedemstat" ] } }, "by_drug": { "ADEBRELIMAB": { "n": 67, "n_observational": 7, "n_active": 61, "n_withdrawn": 1, "trials": [ { "nct": "NCT06177925", "title": "A Phase \u2161 Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC", "status": "RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188650", "title": "The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study", "status": "RECRUITING", "last_update": "2024-01-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424899", "title": "A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06467617", "title": "Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475209", "title": "Adebrelimab + Apatinib in SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06480864", "title": "Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-01-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06483282", "title": "A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06485544", "title": "Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06512051", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06527898", "title": "Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562920", "title": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589778", "title": "A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06610734", "title": "Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06739928", "title": "Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC", "status": "RECRUITING", "last_update": "2024-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06775275", "title": "A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06853678", "title": "Second-line Immunotherapy for ES-SCLC", "status": "RECRUITING", "last_update": "2025-03-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06936735", "title": "A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943235", "title": "Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07141264", "title": "Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07170995", "title": "Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07229729", "title": "A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232849", "title": "A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559786", "title": "A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562337", "title": "SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05416775", "title": "Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05496166", "title": "The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-05-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05738317", "title": "Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment", "status": "UNKNOWN", "last_update": "2023-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932264", "title": "Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06182800", "title": "Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236997", "title": "Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299371", "title": "Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06300424", "title": "Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06306560", "title": "A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332950", "title": "Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06335355", "title": "A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434103", "title": "Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06478264", "title": "A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06594874", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597513", "title": "Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06614621", "title": "A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06672133", "title": "Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06685653", "title": "Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06700421", "title": "Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735508", "title": "MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773156", "title": "Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784206", "title": "Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786312", "title": "A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914050", "title": "Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963502", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031154", "title": "A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07035392", "title": "Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063407", "title": "Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069270", "title": "A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07200154", "title": "Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281209", "title": "A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357532", "title": "Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381543", "title": "Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07398560", "title": "Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464327", "title": "A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07560358", "title": "Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07567326", "title": "Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07583550", "title": "Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07704645", "title": "The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07798947", "title": "A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07822542", "title": "A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 179, "n_observational": 21, "n_active": 73, "n_withdrawn": 5, "trials": [ { "nct": "NCT04253964", "title": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467723", "title": "Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04865250", "title": "Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05284539", "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer", "status": "RECRUITING", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317858", "title": "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834413", "title": "Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110572", "title": "Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation", "status": "RECRUITING", "last_update": "2024-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161532", "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179069", "title": "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429696", "title": "PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06529081", "title": "Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616623", "title": "Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646276", "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06663098", "title": "Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).", "status": "RECRUITING", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712355", "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731270", "title": "Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06771518", "title": "Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908993", "title": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130032", "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226999", "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322341", "title": "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472517", "title": "DAREON \u00ae -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545954", "title": "DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07654400", "title": "A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846416", "title": "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01903993", "title": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"", "status": "COMPLETED", "last_update": "2019-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298153", "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma", "status": "TERMINATED", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02366143", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367781", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367794", "title": "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]", "status": "COMPLETED", "last_update": "2022-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403271", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409342", "title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409355", "title": "A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)", "status": "TERMINATED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02463994", "title": "A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC", "status": "COMPLETED", "last_update": "2019-02-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02525757", "title": "MPDL3280A With Chemoradiation for Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599454", "title": "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2019-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657434", "title": "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716038", "title": "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC", "status": "COMPLETED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02748889", "title": "Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848651", "title": "A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "status": "TERMINATED", "last_update": "2023-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927301", "title": "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02994576", "title": "Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03059667", "title": "Immunotherapy as Second-line in Patient With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03138889", "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191786", "title": "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Na\u00efve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262454", "title": "Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03438318", "title": "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455556", "title": "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03456063", "title": "A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498222", "title": "Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin", "status": "WITHDRAWN", "last_update": "2020-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526900", "title": "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na\u00efve Patients With Asymptomatic Brain Metastasis", "status": "COMPLETED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03540420", "title": "Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03563716", "title": "A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Na\u00efve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616691", "title": "Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC", "status": "UNKNOWN", "last_update": "2018-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03644823", "title": "Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03689855", "title": "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "COMPLETED", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03713944", "title": "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na\u00efve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735121", "title": "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801304", "title": "Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03830918", "title": "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836066", "title": "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03896074", "title": "Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922997", "title": "A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976518", "title": "Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)", "status": "COMPLETED", "last_update": "2024-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977194", "title": "Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03991403", "title": "Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC", "status": "UNKNOWN", "last_update": "2023-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028050", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042558", "title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059887", "title": "Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04099836", "title": "Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib", "status": "TERMINATED", "last_update": "2023-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101357", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411", "status": "TERMINATED", "last_update": "2025-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04147351", "title": "A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04194203", "title": "A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Na\u00efve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)", "status": "COMPLETED", "last_update": "2024-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221529", "title": "Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide", "status": "COMPLETED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245085", "title": "ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256421", "title": "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04267237", "title": "A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04294810", "title": "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310020", "title": "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334941", "title": "Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04367311", "title": "Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors \u2265 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04373369", "title": "Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04402788", "title": "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial", "status": "SUSPENDED", "last_update": "2026-09-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426825", "title": "A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04440735", "title": "A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04462276", "title": "Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease", "status": "COMPLETED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471415", "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471428", "title": "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04480372", "title": "SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II", "status": "COMPLETED", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487756", "title": "Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512430", "title": "Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04549428", "title": "Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC", "status": "TERMINATED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560972", "title": "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04619797", "title": "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622228", "title": "Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631029", "title": "Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04636762", "title": "A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665856", "title": "Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04690686", "title": "Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730999", "title": "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776447", "title": "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04832854", "title": "A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04911166", "title": "Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy", "status": "TERMINATED", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04919369", "title": "All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923776", "title": "Liver Directed RT + Chemo-immunotherapy for ES-SCLC", "status": "TERMINATED", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958811", "title": "Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984811", "title": "NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC", "status": "TERMINATED", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989283", "title": "Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992715", "title": "PD-L1 Expression in Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997382", "title": "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007769", "title": "Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "WITHDRAWN", "last_update": "2021-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191797", "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224141", "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05240131", "title": "A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468489", "title": "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05595460", "title": "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05689671", "title": "Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703997", "title": "FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction", "status": "NOT_YET_RECRUITING", "last_update": "2023-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05746481", "title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05781308", "title": "Combination of Paclitaxel-bevacizumab \u00b1 Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05825625", "title": "NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06077500", "title": "DAREON\u1d40\u1d39-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06195683", "title": "Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS \u2265 50%: a Prospective, Single-center, Single-arm Phase 2 Study.", "status": "UNKNOWN", "last_update": "2024-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06719336", "title": "Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190027", "title": "Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07707895", "title": "DAREON\u00ae-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 37, "n_observational": 0, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07224971", "title": "Impact of Circadian Rhythm on Immunotherapy", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02222922", "title": "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349633", "title": "Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)", "status": "TERMINATED", "last_update": "2021-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02395172", "title": "Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576574", "title": "Avelumab in First-line NSCLC (JAVELIN Lung 100)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "status": "TERMINATED", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050554", "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03268057", "title": "VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-05-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03270176", "title": "A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy", "status": "COMPLETED", "last_update": "2022-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317496", "title": "Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2023-08-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386929", "title": "Survival Prolongation by Rationale Innovative Genomics", "status": "TERMINATED", "last_update": "2023-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409458", "title": "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472560", "title": "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514719", "title": "PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)", "status": "COMPLETED", "last_update": "2022-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568097", "title": "Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574649", "title": "QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03717155", "title": "Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC", "status": "COMPLETED", "last_update": "2022-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03815643", "title": "Avelumab Program Rollover Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173507", "title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551885", "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04571632", "title": "Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04601402", "title": "GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03631706", "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03840902", "title": "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03840915", "title": "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04297748", "title": "Bioimaging Study of 89Zr-M7824 in NSCLC", "status": "TERMINATED", "last_update": "2023-01-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396535", "title": "Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003649", "title": "Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004225", "title": "Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049218", "title": "Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00776295", "title": "Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COSIBELIMAB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03212404", "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04786964", "title": "Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 177, "n_observational": 23, "n_active": 85, "n_withdrawn": 12, "trials": [ { "nct": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499053", "title": "Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550104", "title": "A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585490", "title": "Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892953", "title": "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992780", "title": "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061550", "title": "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136846", "title": "Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568212", "title": "Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696782", "title": "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834413", "title": "Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05903092", "title": "MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223711", "title": "Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC", "status": "RECRUITING", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371482", "title": "Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)", "status": "RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429696", "title": "PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464068", "title": "AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06484491", "title": "IMPT Dose Escalation for NSCLC (HyDose)", "status": "RECRUITING", "last_update": "2026-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498635", "title": "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial", "status": "RECRUITING", "last_update": "2026-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06529081", "title": "Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667908", "title": "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680050", "title": "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908070", "title": "Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07055581", "title": "Durvalumab as Consolidation for Patients LS-SCLC", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361497", "title": "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554339", "title": "A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)", "status": "RECRUITING", "last_update": "2026-09-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000947", "title": "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02087423", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088112", "title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02125461", "title": "A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250326", "title": "Safety and Efficacy Study of Nab\u00ae-Paclitaxel With CC-486 or Nab\u00ae-Paclitaxel With Durvalumab, and Nab\u00ae-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352948", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403271", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02452463", "title": "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy", "status": "TERMINATED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454933", "title": "Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492867", "title": "A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572843", "title": "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639026", "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02673814", "title": "Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2016-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2023-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003962", "title": "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03004105", "title": "MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2018-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03022500", "title": "Pulmonary sarcomatoid_MEDI4736+Treme", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03130764", "title": "Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC", "status": "WITHDRAWN", "last_update": "2017-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03141359", "title": "Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03148327", "title": "Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy", "status": "TERMINATED", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164616", "title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "status": "TERMINATED", "last_update": "2023-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319316", "title": "Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)", "status": "WITHDRAWN", "last_update": "2022-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03446547", "title": "Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519971", "title": "Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589547", "title": "Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620669", "title": "1st Line Durvalumab in PS 2 NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03706690", "title": "A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732274", "title": "Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC", "status": "COMPLETED", "last_update": "2025-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732664", "title": "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03794544", "title": "Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800134", "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818776", "title": "Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC", "status": "TERMINATED", "last_update": "2024-02-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833154", "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03871153", "title": "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916419", "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03963414", "title": "A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC", "status": "TERMINATED", "last_update": "2023-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03965468", "title": "Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03999710", "title": "Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003246", "title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062708", "title": "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04078152", "title": "Durvalumab Long-Term Safety and Efficacy Study", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04108026", "title": "Immunotherapy in Patient With Poor General Condition", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04163432", "title": "Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC", "status": "TERMINATED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224337", "title": "Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245514", "title": "Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249362", "title": "Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy", "status": "COMPLETED", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255836", "title": "Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262388", "title": "A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287894", "title": "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04314297", "title": "Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study", "status": "UNKNOWN", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351256", "title": "Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356222", "title": "Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04361825", "title": "Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects", "status": "COMPLETED", "last_update": "2024-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372927", "title": "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy", "status": "TERMINATED", "last_update": "2023-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04381494", "title": "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04392505", "title": "Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04416633", "title": "Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC", "status": "COMPLETED", "last_update": "2024-11-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04441138", "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449861", "title": "Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04470674", "title": "Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (\u2265 50%) NSCLC Patients", "status": "WITHDRAWN", "last_update": "2022-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472949", "title": "Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04525391", "title": "AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "status": "TERMINATED", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585477", "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)", "status": "SUSPENDED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602533", "title": "Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04607954", "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660097", "title": "Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Na\u00efve Patients With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712903", "title": "Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716946", "title": "Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745689", "title": "Study of AZD2811 + Durvalumab in ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04748419", "title": "Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762030", "title": "Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04765709", "title": "Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870112", "title": "A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895579", "title": "Lung Cancer With Copanlisib and Durvalumab", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944173", "title": "SCION: SABR and Checkpoint Inhibition of NSCLC", "status": "WITHDRAWN", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982549", "title": "A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2021-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985851", "title": "To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.", "status": "UNKNOWN", "last_update": "2023-12-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008861", "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy", "status": "UNKNOWN", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092412", "title": "Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128630", "title": "Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.", "status": "UNKNOWN", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161533", "title": "Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial", "status": "WITHDRAWN", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198830", "title": "Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05223647", "title": "Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267392", "title": "Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298423", "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383001", "title": "Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)", "status": "WITHDRAWN", "last_update": "2022-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403723", "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC", "status": "SUSPENDED", "last_update": "2026-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443971", "title": "Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen", "status": "TERMINATED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451173", "title": "Combining ICI With SBRT or HypoFrx-RT for ES NSCLC", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484583", "title": "Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05757843", "title": "Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796089", "title": "Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05856695", "title": "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911308", "title": "Abequolixron (RGX-104) and Durvalumab in Lung Cancer", "status": "TERMINATED", "last_update": "2025-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083454", "title": "Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06124118", "title": "Tumor Treating Fields for Locally Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419179", "title": "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06606847", "title": "A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06694454", "title": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "SUSPENDED", "last_update": "2026-09-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06719336", "title": "Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998719", "title": "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07146230", "title": "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07672223", "title": "A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759492", "title": "Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 20, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT05024214", "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123754", "title": "Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06698965", "title": "Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin", "status": "RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06734182", "title": "Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05055167", "title": "Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068427", "title": "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05203276", "title": "Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05243355", "title": "Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC", "status": "UNKNOWN", "last_update": "2022-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360979", "title": "A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05414630", "title": "A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05529355", "title": "Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05534113", "title": "Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05685550", "title": "Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904015", "title": "The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910034", "title": "Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06108726", "title": "A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06279754", "title": "Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06618391", "title": "Local Injection and Systemic Therapy in the Treatment of NSCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283198", "title": "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07818304", "title": "SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "INCB-086550": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04629339", "title": "Study of INCB086550 in Select Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVITOCLAX": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00445198", "title": "A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520778", "title": "Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03366103", "title": "Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT05027867", "title": "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05705466", "title": "Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OBATOCLAX": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00405951", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521144", "title": "Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2015-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00682981", "title": "A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)", "status": "COMPLETED", "last_update": "2016-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01563601", "title": "Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2012-08-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "OBLIMERSEN": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003103", "title": "Chemotherapy in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005032", "title": "Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017251", "title": "Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030641", "title": "Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2014-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00042978", "title": "Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ROVALPITUZUMAB TESIRINE": { "n": 10, "n_observational": 1, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01901653", "title": "Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674568", "title": "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819999", "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03033511", "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)", "status": "TERMINATED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03061812", "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03086239", "title": "A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02890069", "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat", "status": "COMPLETED", "last_update": "2023-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SUGEMALIMAB": { "n": 8, "n_observational": 3, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT05623267", "title": "Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT", "status": "RECRUITING", "last_update": "2023-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05940532", "title": "A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2023-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217757", "title": "Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06617416", "title": "A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06987734", "title": "Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247227", "title": "Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190027", "title": "Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TARLATAMAB": { "n": 28, "n_observational": 2, "n_active": 26, "n_withdrawn": 1, "trials": [ { "nct": "NCT06598306", "title": "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957314", "title": "A Study of Hospital-at-Home for People Receiving Tarlatamab", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016230", "title": "Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037758", "title": "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07203053", "title": "A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242547", "title": "Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07402343", "title": "Tarlatamab for SCLC Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423585", "title": "Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778316", "title": "Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07803848", "title": "Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04885998", "title": "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060016", "title": "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05740566", "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06117774", "title": "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745323", "title": "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06816394", "title": "Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328490", "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer", "status": "WITHDRAWN", "last_update": "2026-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699237", "title": "A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VENETOCLAX": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02391480", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer", "status": "COMPLETED", "last_update": "2019-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04274907", "title": "A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression", "status": "TERMINATED", "last_update": "2021-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543916", "title": "Venetoclax and Irinotecan in Relapsed/Refractory SCLC", "status": "WITHDRAWN", "last_update": "2021-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07713732", "title": "TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }